Full history for every metric is available with a Kvantra account
Celltrion Healthcare Co., Ltd. (091990.KQ)
Key financial summary
Financials in KRW| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | KRW bn | 921 | 713 | 1,101 | 1,628 | 1,804 | 1,972 | 2,218 |
| Operating profit | KRW bn | 229 | 173 | |||||
| Net profit | KRW bn | 166 | 11 | 65 | 240 | 153 | 147 | 43 |
| EPS reported | KRW | 912.0 | 274.5 | |||||
| Operating cashflow per share | KRW | 1,253 | 1,253 | |||||
| Capex per share | KRW | 5.46 | 5.46 | |||||
| FCF per share | KRW | 1,248 | 1,248 | |||||
| Free cash flow | KRW bn | 201 | 129 | |||||
| Net debt | KRW bn | -539 | -400 | |||||
| Book value equity | KRW bn | 2,062 | 2,069 | |||||
| Book value per share | KRW | 12,776 | 12,977 | |||||
| Number of shares | m | 161.37 | 159.43 | |||||
| DPS (TTM paid) | KRW | 130.0 | 130.0 |
Financial summary
Financials in KRW| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 63.59 | - | |||||
| P/B LTM | x | 4.49 | 5.19 | |||||
| P/S LTM | x | 4.69 | 4.84 | |||||
| P/FCF LTM | x | 46.01 | 83.14 | |||||
| EV/EBITDA LTM | x | 37.58 | 57.48 | |||||
| EV/Sales LTM | x | 4.46 | 4.66 | |||||
| Earnings Yield LTM | % | 1.57% | 1.20% | |||||
| FCF Yield | % | 2.17% | 1.20% | |||||
| Quality | ||||||||
| ROE | % | 7.14% | 7.06% | |||||
| ROIC | % | 7.13% | 7.13% | |||||
| Operating margin | % | 11.61% | 11.61% | |||||
| Gross margin | % | 28.48% | 28.48% | |||||
| FCF/Sales | % | 10.20% | 10.20% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -2.49% | -81.29% | |||||
| Sales Growth YoY | % | +9.29% | +8.89% | |||||
| Net Income Growth YoY | % | -3.53% | -81.81% | |||||
| FCF Growth | % | - | +52.54% | |||||
| Operating Profit Growth | % | +14.77% | -33.89% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.43% | 0.17% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 27.08% | 45.94% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -1.96 | -1.96 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -5.82% | -3.73% | |||||
| Net debt/Equity | x | -0.26 | -0.19 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Celltrion Healthcare Co., Ltd. (091990.KQ)
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free